KPMG-INTERNATIONAL
As General Counsel and in-house legal teams contend with the increasing pressures facing their organizations in the wake of COVID-19, there is an urgent need to rethink delivery models and transform legal function operations. While the move to digitize and automate the legal function was already underway before COVID-19, it is now a commercial imperative, and the scope and remit is wider than before as the pandemic situation has intensified the need for organizations to transform.
In response, a Global Legal Operations Transformation Services offering has been launched across KPMG firms, which is designed to provide clients with a wide range of global strategies and cross-border capabilities to help meet the challenges they face.
“I believe KPMG’s Global Legal Operations Transformation Services teams are ‘global,’ both in terms of the geographic coverage but also the strategies offered,” says Stuart Fuller , Head of Global Legal Services, KPMG International. “Practice leaders are senior, experienced, and work together in KPMG firms across Europe, the Americas and the Asia Pacific region. They have a laser focus on results, and they are delivering significant and measurable improvement for legal functions across KPIs, such as productivity, customer satisfaction and quality measures―results that are crucial for organizations in the current climate.”
The KPMG Legal Operations Transformation Services practice leadership team includes Andreas Bong , Nicola Brooks , Philipp Glock , Eric Gorman , Kimberly Tan Majure and David Murray , and with an imminent announcement of a significant further partner hire. These leaders are supported by their team members in country firms, and professionals across the global organization, including MBAs, lawyers, legal technologists, data scientists and specialists in operational excellence. Their diverse and complementary skillsets, and combined experience, unite under KPMG’s global methodology to provide significant value to clients.
“We draw on all of the strengths of KPMG professionals across our firms, not just in legal and technology, but also Lean Six Sigma, Human-Centred Design and Systems Thinking. Together, our organization has achieved a substantial track record of implementing and running the transformation opportunities that we identify,” says Fuller. “KPMG Law is a combination of skills and approaches: we have over 2,700 lawyers in 81 jurisdictions advising on complex advisory and regulatory matters, and large transactions; we also provide global solutions such as business reorganization, global entity management and mass claims, offering an integrated service and advice. The new Legal Operations Transformation Service enables KPMG firms to handle large-scale business in a more efficient and technologically-enabled way and is only the first in a number of capabilities and services that we plan to provide in this space.”
The Legal Operations Transformation Services team brings more than 14 years of credentials and experience in the legal transformation space, with recent and current engagements across multinational organizations in the financial services, asset management, automotive, insurance and consumer goods sectors. In the past two years alone, KPMG firms have delivered cost savings of more than US$200 million across a range of services, including process optimization, automation, contract life cycle management, managed services and productized legal solutions.
David Linke , the Global Head of Tax & Legal Services for KPMG International, says “KPMG firms have a record of innovation and success in Tax Transformation under the banner of ’Tax Reimagined.’ Legal Operations Transformation Services are one of KPMG firms’ leading service offerings. While COVID-19 has accelerated the trends that we were already seeing for legal transformation, the post-COVID world will require legal and compliance teams to be even more efficient, even more engaged with the business and to play a key role in driving the customer experience, revenue and cash conversion cycles. Never has a global and integrated approach to transformation been more in demand than in the current climate. KPMG professionals are focused on bringing the best of our global capabilities, expertise and solutions to legal departments.”
* Important note: Certain member firms of the KPMG global organization, including the US firm, KPMG LLP, do not provide legal services or have KPMG Law service entities. In the US, these Legal Operations Transformation Services will be provided through the Advisory and Tax functions. Some or all the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 147 countries and territories and have more than 219,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such.
KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013006153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom